Author:
Bindels Jill,Ramaekers Bram,Ramos Isaac Corro,Mohseninejad Leyla,Knies Saskia,Grutters Janneke,Postma Maarten,Al Maiwenn,Feenstra Talitha,Joore Manuela
Funder
Netherlands Organization for Health Research and Development
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference25 articles.
1. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779–87.
2. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Handbooks in health economic evaluation series. Oxford: Oxford University Press; 2006.
3. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007;16(2):195–209. doi: 10.1002/hec.1161 .
4. Grutters JP, Abrams KR, de Ruysscher D, Pijls-Johannesma M, Peters HJ, Beutner E, et al. When to wait for more evidence? Real options analysis in proton therapy. Oncologist. 2011;16(12):1752–61. doi: 10.1634/theoncologist.2011-0029 .
5. Blommestein HM, Franken MG, Verelst SG, van Agthoven M, Huijgens PC, Uyl-de Groot CA. Access to expensive cancer drugs in Dutch daily practice: should we be concerned? Neth J Med. 2014;72(4):235–41.